Legend Biotech Corp ADR (NASDAQ: LEGN) on Friday, soared 3.16% from the previous trading day, before settling in for the closing price of $34.18. Within the past 52 weeks, LEGN’s price has moved between $30.17 and $69.24.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 59.11% annually for the last half of the decade. The company achieved an average annual earnings per share of 42.15%. With a float of $180.94 million, this company’s outstanding shares have now reached $183.45 million.
In an organization with 1826 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 60.75%, operating margin of -53.92%, and the pretax margin is -66.41%.
Legend Biotech Corp ADR (LEGN) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Legend Biotech Corp ADR is 1.37%, while institutional ownership is 53.50%. The most recent insider transaction that took place on Jan 10 ’25, was worth 72,553. Before that another transaction happened on Dec 24 ’24, when Company’s Officer proposed sale 63,061 for $32.45, making the entire transaction worth $2,046,512.
Legend Biotech Corp ADR (LEGN) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 42.15% per share during the next fiscal year.
Legend Biotech Corp ADR (NASDAQ: LEGN) Trading Performance Indicators
Legend Biotech Corp ADR (LEGN) is currently performing well based on its current performance indicators. A quick ratio of 4.90 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.91, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Legend Biotech Corp ADR (LEGN)
Let’s dig in a bit further. During the last 5-days, its volume was 1.2 million. That was inferior than the volume of 1.27 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 30.27%. Additionally, its Average True Range was 1.83.
During the past 100 days, Legend Biotech Corp ADR’s (LEGN) raw stochastic average was set at 23.56%, which indicates a significant decrease from 34.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.41% in the past 14 days, which was higher than the 49.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.31, while its 200-day Moving Average is $44.16. However, in the short run, Legend Biotech Corp ADR’s stock first resistance to watch stands at $35.82. Second resistance stands at $36.39. The third major resistance level sits at $37.33. If the price goes on to break the first support level at $34.32, it is likely to go to the next support level at $33.38. Assuming the price breaks the second support level, the third support level stands at $32.81.
Legend Biotech Corp ADR (NASDAQ: LEGN) Key Stats
Market capitalization of the company is 6.47 billion based on 182,634K outstanding shares. Right now, sales total 285,140 K and income totals -518,250 K. The company made 160,210 K in profit during its latest quarter, and -125,320 K in sales during its previous quarter.
